Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Virtual screening for kinase targets.

Ingo Muegge1, Istvan J Enyedy

  • 1Boehringer Ingelheim Pharmaceuticals, Inc, 900 Ridgebury Road, Ridgefield, CT 06877-0368, USA. imugge@rdg.boehringer-ingelheim.com

Current Medicinal Chemistry
|March 23, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How does machine learning augment alchemical binding free energy calculations?

Future medicinal chemistry·2025
Same author

Perspectives on current approaches to virtual screening in drug discovery.

Expert opinion on drug discovery·2024
Same author

Advances in virtual screening.

Drug discovery today. Technologies·2024
Same author

Prediction of Human Clearance Using In Silico Models with Reduced Bias.

Molecular pharmaceutics·2024
Same author

Recent Advances in Alchemical Binding Free Energy Calculations for Drug Discovery.

ACS medicinal chemistry letters·2023
Same author

How do we further enhance 2D fingerprint similarity searching for novel drug discovery?

Expert opinion on drug discovery·2022
Same journal

LncRNA signature associated with amino acid metabolism: A novel prognostic tool for Clear Cell Renal Cell Carcinoma.

Current medicinal chemistry·2026
Same journal

HRI Kinase Modulation by BTdCPU as a Therapeutic Strategy for Bortezomib Resistance in Prostate Cancer.

Current medicinal chemistry·2026
Same journal

EGFR Dysregulation in Cancer: From Molecular Mechanisms and Key Mutations to Evolving TKI Strategies and Resistance Mitigation.

Current medicinal chemistry·2026
Same journal

DHRS2 as a Novel Thalidomide Target Regulating Mitophagy and Inflammation in Head and Neck Squamous Cell Carcinoma.

Current medicinal chemistry·2026
Same journal

Synthetic AtMP2 from Anabas testudineus: Comprehensive ADMET and In Vivo Toxicity Assessment to Enable Future Therapeutic Development.

Current medicinal chemistry·2026
Same journal

Screening of Medicinal and Edible Homology Substances for Diabetic Kidney Disease Based on GraphBAN.

Current medicinal chemistry·2026
See all related articles

Virtual screening of kinases, crucial for drug discovery, faces challenges. This study explores factors influencing kinase inhibitor screening, including database choice and binding pocket variations, offering insights for CDK2, SRC, and ErbB2 targets.

Area of Science:

  • Biochemistry and Structural Biology
  • Medicinal Chemistry and Drug Discovery
  • Computational Chemistry and Cheminformatics

Background:

  • Kinases are critical targets in drug discovery, with numerous 3D structures publicly available.
  • High homology within the kinase family presents opportunities for homology modeling and virtual screening.
  • Despite potential, virtual screening studies for kinases remain relatively scarce.

Purpose of the Study:

  • To investigate the challenges and best practices in virtual screening for kinase drug discovery.
  • To analyze factors affecting the ranking of potential kinase inhibitors, including database, docking, and scoring methods.
  • To present new case studies on Cyclin-Dependent Kinase 2 (CDK2), SRC kinase, and ErbB2.

Main Methods:

  • Hybrid approach combining existing knowledge with new studies on CDK2 and SRC kinase.

Related Experiment Videos

  • Analysis of how screening database, docking scheme, and scoring function impact virtual screening results.
  • Investigation of the influence of compound activity and minor binding pocket alterations on target identification.
  • In silico screening for irreversible ErbB2 inhibitors.

    • Main Results:

    • Identified key factors influencing the reliability and success of virtual screening for kinase targets.
    • Demonstrated the impact of subtle changes in binding pocket conformation on screening outcomes.
    • Successfully applied in silico methods to identify potential irreversible inhibitors for ErbB2.

    Conclusions:

    • Virtual screening for kinases requires careful consideration of multiple parameters to overcome inherent challenges.
    • Understanding factors like database selection and scoring function is crucial for effective drug discovery.
    • In silico approaches, including virtual screening, are valuable tools for identifying novel kinase inhibitors, exemplified by the ErbB2 case study.